Meanwhile, it has been reported that the reduction of HMGB1 is sufficient to impair HSC self-renewal and promote apoptotic cell death in MDS and that inhibitors of HMGB1 signaling provided a first-in-class therapeutic option for patients with MDS[44]. Here, HMGB1 is linked to myelodysplastic syndrome.